Regulators have passed GlaxoSmithKline’s prostate drug Duodart for use in the EU, the company has announced.
The two-in-one treatment, used to alleviate the symptoms of an enlarged prostate, contains dutasteride, currently marketed as Avodart, and tamsulosin, sold as Flomax.
Approval was granted in Germany under the EU’s decentralised approval procedure, meaning it is applicable across the 27-member bloc. Individual national licences are expected to follow.
Prostate enlargement is an increasingly common problem for men as they age. Almost four in 10 over-65s have the condition, which occurs when there is an overgrowth of cells in the prostate gland, blocking the flow of urine.
It is thought that Glaxo eventually plans to use Avodart as a prostate cancer treatment after earlier research showed the drug reduced the risk of contracting the condition by around 25%.